EVFM Evofem Biosciences Inc.

4.98
-0.06  -1%
Previous Close 5.04
Open 5
Price To Book 6.47
Market Cap 232,073,269
Shares 46,601,058
Volume 13,468
Short Ratio
Av. Daily Volume 25,857
Stock charts supplied by TradingView

NewsSee all news

  1. Evofem Biosciences to Present at Cantor Global Healthcare Conference on October 4, 2019

    SAN DIEGO, Sept. 25, 2019 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ:EVFM), a clinical-stage biopharmaceutical company, will present and host investor meetings at the upcoming 2019 Cantor Global Healthcare

  2. Microbiotica Appoints Thomas Lynch as Independent Non-Executive Chairman

    Microbiotica, a leading player in microbiome-based therapeutics and biomarkers, announces the appointment of Thomas Lynch as the new non-Executive Chairman of its Board, from 1 September 2019.

  3. Evofem Biosciences Completes Phase 2b 'AMPREVENCE' Trial of Amphora for Prevention of Chlamydia and Gonorrhea in Women

    SAN DIEGO, Aug. 26, 2019 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ:EVFM) ("Evofem" or the "Company") today announced the last patient has completed her last visit in AMPREVENCE, the Phase 2b

  4. Evofem Biosciences to Present at Upcoming Healthcare Conferences

    SAN DIEGO, Aug. 22, 2019 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ:EVFM), a clinical-stage biopharmaceutical company, is set to present at two healthcare equity conferences in early September.

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2b data due November 2019.
Amphora - AMPREVENCE
Prevention of urogenital Chlamydia trachomatis infection in women
NDA to be refiled 4Q 2019.
Amphora - AMPOWER
contraceptive vaginal gel

Latest News

  1. Evofem Biosciences to Present at Cantor Global Healthcare Conference on October 4, 2019

    SAN DIEGO, Sept. 25, 2019 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ:EVFM), a clinical-stage biopharmaceutical company, will present and host investor meetings at the upcoming 2019 Cantor Global Healthcare

  2. Microbiotica Appoints Thomas Lynch as Independent Non-Executive Chairman

    Microbiotica, a leading player in microbiome-based therapeutics and biomarkers, announces the appointment of Thomas Lynch as the new non-Executive Chairman of its Board, from 1 September 2019.

  3. Evofem Biosciences Completes Phase 2b 'AMPREVENCE' Trial of Amphora for Prevention of Chlamydia and Gonorrhea in Women

    SAN DIEGO, Aug. 26, 2019 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ:EVFM) ("Evofem" or the "Company") today announced the last patient has completed her last visit in AMPREVENCE, the Phase 2b

  4. Evofem Biosciences to Present at Upcoming Healthcare Conferences

    SAN DIEGO, Aug. 22, 2019 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ:EVFM), a clinical-stage biopharmaceutical company, is set to present at two healthcare equity conferences in early September.